Literature DB >> 17298437

A metabolomics perspective of human brain tumours.

Julian L Griffin1, Risto A Kauppinen.   

Abstract

During the past decade or so, a wealth of information about metabolites in various human brain tumour preparations (cultured cells, tissue specimens, tumours in vivo) has been accumulated by global profiling tools. Such holistic approaches to cellular biochemistry have been termed metabolomics. Inherent and specific metabolic profiles of major brain tumour cell types, as determined by proton nuclear magnetic resonance spectroscopy ((1)H MRS), have also been used to define metabolite phenotypes in tumours in vivo. This minireview examines the recent advances in the field of human brain tumour metabolomics research, including advances in MRS and mass spectrometry technologies, and data analysis.

Entities:  

Mesh:

Year:  2007        PMID: 17298437     DOI: 10.1111/j.1742-4658.2007.05676.x

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  37 in total

Review 1.  Metabolomic signature of brain cancer.

Authors:  Renu Pandey; Laura Caflisch; Alessia Lodi; Andrew J Brenner; Stefano Tiziani
Journal:  Mol Carcinog       Date:  2017-07-17       Impact factor: 4.784

Review 2.  Integrative biological analysis for neuropsychopharmacology.

Authors:  Mark R Emmett; Roger A Kroes; Joseph R Moskal; Charles A Conrad; Waldemar Priebe; Fernanda Laezza; Anke Meyer-Baese; Carol L Nilsson
Journal:  Neuropsychopharmacology       Date:  2013-06-26       Impact factor: 7.853

3.  Analyzing LC/MS metabolic profiling data in the context of existing metabolic networks.

Authors:  Tianwei Yu; Yun Bai
Journal:  Curr Metabolomics       Date:  2013-01-01

Review 4.  Magnetic resonance spectroscopy in metabolic and molecular imaging and diagnosis of cancer.

Authors:  Kristine Glunde; Dmitri Artemov; Marie-France Penet; Michael A Jacobs; Zaver M Bhujwalla
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

Review 5.  Metabolic tumor imaging using magnetic resonance spectroscopy.

Authors:  Kristine Glunde; Zaver M Bhujwalla
Journal:  Semin Oncol       Date:  2011-02       Impact factor: 4.929

6.  The metabolomic profile during isoflurane anesthesia differs from propofol anesthesia in the live rodent brain.

Authors:  Rany Makaryus; Hedok Lee; Mei Yu; Shaonan Zhang; S David Smith; Mario Rebecchi; Peter S Glass; Helene Benveniste
Journal:  J Cereb Blood Flow Metab       Date:  2011-01-26       Impact factor: 6.200

Review 7.  Proteomics of gliomas: initial biomarker discovery and evolution of technology.

Authors:  Juliya Kalinina; Junmin Peng; James C Ritchie; Erwin G Van Meir
Journal:  Neuro Oncol       Date:  2011-09       Impact factor: 12.300

8.  Metabolomic profiling of human serum in lung cancer patients using liquid chromatography/hybrid quadrupole time-of-flight mass spectrometry and gas chromatography/mass spectrometry.

Authors:  Yingrong Chen; Zhihong Ma; Aiying Li; Hongwei Li; Bin Wang; Jing Zhong; Lishan Min; Licheng Dai
Journal:  J Cancer Res Clin Oncol       Date:  2014-10-08       Impact factor: 4.553

Review 9.  Bioactive food components and cancer-specific metabonomic profiles.

Authors:  Young S Kim; John A Milner
Journal:  J Biomed Biotechnol       Date:  2010-11-11

Review 10.  Metabolomics-based methods for early disease diagnostics.

Authors:  G A Nagana Gowda; Shucha Zhang; Haiwei Gu; Vincent Asiago; Narasimhamurthy Shanaiah; Daniel Raftery
Journal:  Expert Rev Mol Diagn       Date:  2008-09       Impact factor: 5.225

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.